|
시장보고서
상품코드
2054984
이뇨제 시장 : 약제 클래스별, 적응증별, 투여 경로별, 작용기전별, 연령층별, 제형별, 유형별, 유통 채널별, 최종사용자별, 지역별Diuretics Drugs Market, By Drug Class, By Indication, By Route of Administration, By Mechanism of Action, By Age Group, By Formulation Type, By Type, By Distribution Channel, By End User, By Geography |
||||||
이뇨제 시장은 2026년에 299억 8,000만 달러로 추정되며, 2033년까지 444억 9,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 5.8%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 299억 8,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 5.80% | 2033년 시장 규모 예측 : | 444억 9,000만 달러 |
세계 이뇨제 시장은 제약 업계에서 중요한 부문을 차지하고 있으며, 소변 생성을 촉진하고 체내의 과잉 수분 및 나트륨 배출을 돕도록 특별히 고안된 의약품을 포함하고 있습니다. 일반적으로 ‘수약’이라 불리는 이뇨제는 고혈압, 심부전, 부종, 신장 질환 등 다양한 심혈관 및 신장 질환의 관리에 중요한 역할을 하고 있습니다.
이러한 치료제는 주로 신장의 네프론에 작용하여 나트륨의 재흡수를 억제하고, 그 결과 체액 배출을 촉진하여 혈액량을 감소시키는 등 서로 다른 작용기전을 통해 효과를 발휘합니다. 이 시장은 티아지드계 및 티아지드 유사 이뇨제, 루프 이뇨제, 칼륨 보존성 이뇨제, 탄산탈수효소 억제제 등 여러 가지 다른 범주의 이뇨제로 구성되어 있으며, 각각은 특정 치료 목적이나 환자군에 대응하고 있습니다. 생활습관병 유병률 증가, 고령화, 그리고 심혈관 건강에 대한 인식 제고가 전 세계 이뇨제 수요의 지속적인 증가에 크게 기여하고 있습니다. 의료 전문가들은 이뇨제가 고혈압 관리의 1차 선택 약물이자 병용 요법의 필수적인 구성 요소라는 점을 점점 더 인식하고 있으며, 이는 선진국과 신흥국 모두에서 시장 확대를 주도하고 있습니다.
시장 역학
세계 이뇨제 시장은 몇 가지 강력한 시장 성장 촉진요인에 힘입어 성장하고 있습니다. 특히 고혈압 및 심혈관 질환의 유병률 급증이 주요 성장 동력이 되고 있습니다. 이러한 질환은 전 세계 수백만 명에게 영향을 미치고 있으며, 장기적인 약물 관리가 필요하기 때문에 이뇨제가 1차 치료제로 자주 사용되기 때문입니다. 세계 인구의 고령화가 급속히 진행되고 있는 점도 시장 확대에 크게 기여하고 있습니다. 고령자는 심혈관 질환이나 신장 질환에 걸리기 쉬워 이뇨제 치료가 필요한 반면, 앉아 있는 시간이 많은 생활 습관과 나트륨 함량이 높은 식습관의 확산으로 인해 젊은 층의 고혈압 발병률도 높아지고 있습니다.
심혈관 질환의 예방 및 관리를 촉진하기 위한 정부의 이니셔티브에 더해, 신흥 시장의 의료 인프라 확충이 시장 성장을 더욱 가속화하고 있습니다. 또한, 여러 동반 질환을 관리하는 데 있어 이뇨제가 비용 대비 효과가 뛰어나고 입증된 효능을 지닌다는 점에 대한 의료진의 인식이 높아지고 있는 점도 시장 성장에 기여하고 있습니다. 그러나 시장에는 뚜렷한 제약도 존재합니다. 예를 들어, ACE 억제제, ARB, 칼슘 채널 차단제 등 환자의 내약성이 더 우수할 가능성이 있는 대체 항고혈압제가 이용 가능하다는 점, 이뇨제 사용에 따른 전해질 균형의 교란, 특히 저나트륨혈증이나 저칼륨혈증에 대한 우려가 처방 의사의 신뢰나 환자의 복약 순응도를 제한할 가능성이 있습니다. 게다가 의약품 승인 절차에 대한 엄격한 규제 요건과 탈수, 신장 기능 장애, 대사 이상 등의 잠재적 부작용이 시장 성장의 걸림돌이 되고 있으며, 단독 이뇨제 처방을 줄일 가능성이 있는 병용 요법에 대한 선호도가 높아지고 있는 점도 이러한 과제를 더욱 심각하게 만들고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 주요 지표를 바탕으로 전 세계 이뇨제 시장의 주요 기업 프로파일을 작성하였습니다. 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적 및 전략.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 세계의 이뇨제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 이뇨제 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 이뇨제 시장 : 약제 클래스별, 2021년-2033년
제5장 세계의 이뇨제 시장 : 적응증별, 2021년-2033년
제6장 세계의 이뇨제 시장 : 투여 경로별, 2021년-2033년
제7장 세계의 이뇨제 시장 : 작용기전별, 2021년-2033년
제8장 세계의 이뇨제 시장 : 연령층별, 2021년-2033년
제9장 세계의 이뇨제 시장 : 제제 유형별, 2021년-2033년
제10장 세계의 이뇨제 시장 : 유형별, 2021년-2033년
제11장 세계의 이뇨제 시장 : 유통 채널별, 2021년-2033년
제12장 세계의 이뇨제 시장 : 최종사용자별, 2021년-2033년
제13장 세계의 이뇨제 시장 : 지역별, 2021년-2033년
제14장 경쟁 구도
제15장 애널리스트의 제안
제16장 참고 문헌 및 조사 방법
LSH 26.06.19Diuretics Drugs Market is estimated to be valued at USD 29.98 Bn in 2026 and is expected to reach USD 44.49 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 29.98 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.80% | 2033 Value Projection: | USD 44.49 Bn |
The global diuretics drugs market represents a critical segment within the pharmaceutical industry, encompassing medications specifically designed to increase urine production and facilitate the elimination of excess water and sodium from the body. Diuretics, commonly referred to as water pills, play an instrumental role in managing various cardiovascular and renal conditions, including hypertension, heart failure, edema, and kidney disorders.
These therapeutic agents function through different mechanisms, primarily targeting the kidneys' nephrons to inhibit sodium reabsorption, consequently promoting fluid elimination and reducing blood volume. The market comprises several distinct categories of diuretics, including thiazide and thiazide-like diuretics, loop diuretics, potassium-sparing diuretics, and carbonic anhydrase inhibitors, each serving specific therapeutic purposes and patient populations. The increasing prevalence of lifestyle-related diseases, aging demographics, and rising awareness of cardiovascular health have significantly contributed to the sustained demand for diuretic medications globally. Healthcare providers increasingly recognize the importance of diuretics as first-line treatments for hypertension management and as essential components in combination therapy regimens, driving market expansion across both developed and emerging economies.
Market Dynamics
The global diuretics drugs market is propelled by several compelling drivers, with the escalating prevalence of hypertension and cardiovascular diseases serving as the primary growth catalyst, as these conditions affect millions worldwide and require long-term pharmacological management where diuretics often represent first-line therapeutic interventions. The rapidly aging global population significantly contributes to market expansion, as elderly individuals demonstrate higher susceptibility to cardiovascular and renal disorders necessitating diuretic therapy, while simultaneously, the increasing adoption of sedentary lifestyles and dietary patterns high in sodium content have amplified the incidence of hypertension among younger demographics.
Government initiatives promoting cardiovascular disease prevention and management, coupled with expanding healthcare infrastructure in emerging markets, further accelerate the market growth, alongside growing physician awareness regarding the cost-effectiveness and proven efficacy of diuretic medications in managing multiple comorbid conditions. However, the market faces notable restraints including the availability of alternative antihypertensive medications such as ACE inhibitors, ARBs, and calcium channel blockers that may offer superior patient tolerance profiles, while concerns regarding electrolyte imbalances, particularly hyponatremia and hypokalemia associated with diuretic usage, may limit prescriber confidence and patient compliance. Additionally, stringent regulatory requirements for drug approval processes and potential adverse effects including dehydration, kidney dysfunction, and metabolic disturbances pose challenges to market growth, compounded by the increasing preference for combination therapies that may reduce standalone diuretic prescriptions.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global diuretics drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Sanofi, Merck & Co Inc, AstraZeneca PLC, Johnson & Johnson, Bayer AG, Bristol-Myers Squibb Company, Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd, Mylan NV (now part of Viatris), Hikma Pharmaceuticals PLC, Lupin Limited, Sun Pharmaceutical Industries Ltd, and Cipla Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global diuretics drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diuretics drugs market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Thiazide Diuretics (e.g., hydrochlorothiazide, chlorthalidone, indapamide, metolazone)"<
- Loop Diuretics (e.g., furosemide, bumetanide, ethacrynic acid, torsemide)"<
- Potassium-Sparing Diuretics (e.g., spironolactone, amiloride, triamterene, eplerenone)"<
- Carbonic Anhydrase Inhibitors (e.g., acetazolamide, methazolamide)"<
- Osmotic Diuretics (e.g., mannitol)"<
- Other Combination Products
- Indication Insights (Revenue, USD Bn, 2021 - 2033)
- Hypertension
- Glaucoma
- Edema (e.g., Heart Failure, Renal Impairment, Cirrhosis)
- Idiopathic Intracranial Hypertension
- Altitude Sickness
- Hyperaldosteronism
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Mechanism of Action Insights (Revenue, USD Bn, 2021 - 2033)
- Sodium-Chloride Cotransporter Inhibitors
- Sodium-Potassium-Chloride Cotransporter Inhibitors
- Aldosterone Antagonists
- Carbonic Anhydrase Blockers
- Osmotic Pressure Regulators
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Pediatric
- Adult
- Geriatric
- Formulation Type Insights (Revenue, USD Bn, 2021 - 2033)
- Tablets/Capsules
- Oral Solutions
- Injections
- Type Insights (Revenue, USD Bn, 2021 - 2033)
- Branded
- Generic
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Homecare Settings
- Research and Academic Institutes
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc
- Novartis AG
- Sanofi
- Merck & Co Inc
- AstraZeneca PLC
- Johnson & Johnson
- Bayer AG
- Bristol-Myers Squibb Company
- Boehringer Ingelheim
- Teva Pharmaceutical Industries Ltd
- Mylan NV (now part of Viatris)
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Sun Pharmaceutical Industries Ltd
- Cipla Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Diuretics Drugs Market, By Drug Class
- Global Diuretics Drugs Market, By Indication
- Global Diuretics Drugs Market, By Route of Administration
- Global Diuretics Drugs Market, By Mechanism of Action
- Global Diuretics Drugs Market, By Age Group
- Global Diuretics Drugs Market, By Formulation Type
- Global Diuretics Drugs Market, By Type
- Global Diuretics Drugs Market, By Distribution Channel
- Global Diuretics Drugs Market, By End User
- Global Diuretics Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Diuretics Drugs Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Thiazide Diuretics (e.g., hydrochlorothiazide, chlorthalidone, indapamide, metolazone)"<
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Loop Diuretics (e.g., furosemide, bumetanide, ethacrynic acid, torsemide)"<
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Potassium-Sparing Diuretics (e.g., spironolactone, amiloride, triamterene, eplerenone)"<
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Carbonic Anhydrase Inhibitors (e.g., acetazolamide, methazolamide)"<
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Osmotic Diuretics (e.g., mannitol)"<
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other Combination Products
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Diuretics Drugs Market, By Indication, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Glaucoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Edema (e.g., Heart Failure, Renal Impairment, Cirrhosis)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Idiopathic Intracranial Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Altitude Sickness
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hyperaldosteronism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Diuretics Drugs Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Diuretics Drugs Market, By Mechanism of Action, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Sodium-Chloride Cotransporter Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Sodium-Potassium-Chloride Cotransporter Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Aldosterone Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Carbonic Anhydrase Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Osmotic Pressure Regulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Diuretics Drugs Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Diuretics Drugs Market, By Formulation Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Tablets/Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Oral Solutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Diuretics Drugs Market, By Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Diuretics Drugs Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
12. Global Diuretics Drugs Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Research and Academic Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
13. Global Diuretics Drugs Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
14. Competitive Landscape
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan NV (now part of Viatris)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
15. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
16. References and Research Methodology
- References
- Research Methodology
- About us
